41 results about "Oral Cavity Squamous Cell Carcinoma" patented technology

The invention belongs to the field of the tumor molecular biological, particularly relating to an oral squamous cell carcinoma diagnostic reagent, kits and medicine. The invention solves the technical problem that the existing medicine and reagent can not early diagnose oral squamous cell carcinoma and can not prevent oral carcinogenesis effectively. The invention oral squamous cell carcinoma diagnostic reagent contains the reagent which can detect expression level of protein RACK1 (activated protein kinase C receptor) and its mRNA content. The oral squamous cell carcinoma kits can be obtained with regular technology. By using the method of screening oral squamous cell carcinoma medicine, the medicine can be screened for preventing oral squamous cell carcinoma medicine, for example: by screen, obtaining effective RACK1 gene and RNA interference molecular, moreover the RNA interference result first reveals the functions of the RNA interference molecular in oral neoplasms apoptosis regulation and oral neoplasms apoptosis treatment, with broad application prospect.

The present invention provides methods of analyzing a sample from a subject having oral epithelial dysplasia or oral SCC or suspected of having oral epithelial dysplasia or oral SCC.

The invention relates to an application of miR-518a-3p in diagnosis of oral carcinoma, in particular to the application of miR-518a-3p and a precursor of miR-518a-3p in preparation of oral squamous cell carcinoma diagnosis preparations. MiRNA microarray data analysis is performed on oral squamous cell carcinoma and adjacent normal tissue with an SAM (selectively amplified microsatellite) method. MiRNA with significant differential expression is screened out, and miR-518a-3p as a novel molecular diagnostic marker associated with the oral squamous cell carcinoma is found. Further, experimental results of fluorescence quantitative PCR verify high expression of miR-518a-3p in oral squamous cell carcinoma tissue and the cell line of the oral squamous cell carcinoma. The novel molecular marker is provided for accurate clinical diagnosis of the oral carcinoma, and a foundation is laid for subsequent development of oral squamous cell carcinoma molecular diagnosis products.

The invention discloses application of a molecular marker to the diagnosis and the treatment of an oral squamous cell carcinoma. A biomarker is GDPD2; discovered through a qPCR (quantitative Polymerase Chain Reaction) experiment, the expression of a GDPD2 gene in tissue and a cell of the oral squamous cell carcinoma is regulated down; the GDPD2 gene overexpression can inhibit the proliferation of the cell and decrease the attack rate of a carcinoma cell. The invention provides application of an accelerant of the GDPD2 to the diagnosis and treatment of the oral squamous cell carcinoma; meanwhile, the invention also discloses a method for inhibiting the cell from proliferating.

The invention discloses a method of stable fluorescence labeling of living cells of oral squamous cell carcinoma. The method is capable of labelling the living cells of the oral squamous cell carcinoma by utilizing fluorescence coupled Nimotuzumab. According to the method, the living cells of the oral squamous cell carcinoma are stably labelled, so that the living cells of the oral squamous cell carcinoma are observed and researched, the experiment measures of researchers are enriched, and the corresponding research fields are expanded.

The invention provides an auxiliary marker for identifying diseases. The auxiliary marker consists of decanoyl carnitine, cysteine and bile acid. The invention also provides a construction method of adisease identification model, which comprises the following steps of: firstly, acquiring a training case set, the subjects in the training case set comprising oral lichen planus disease subjects andoral squamous cell carcinoma disease subjects; secondly, collecting serum samples of the subjects, and carrying out ultra-high performance liquid chromatography quadrupole/electrostatic field orbitraptandem high-resolution mass spectrometry analysis on the serum samples to obtain a plurality of differential metabolites of oral lichen planus and oral squamous cell carcinoma; and thirdly, determining decanoyl carnitine, cysteine and bile acid from the plurality of differential metabolites as a disease identification model by utilizing variable weight importance sorting and a subject working characteristic curve. The invention provides a disease identification model which can be used for identifying and distinguishing oral lichen planus and oral squamous cell carcinoma in the early stage andhas the advantages of being minimally invasive and high in accuracy.

The invention discloses an application of ARRDC2 in evaluating the development process of oral squamous cell carcinoma. According to the invention, by means of high throughput sequencing and bioinformatics analysis, gene ARRDC2, which indicates significant changes in different development processes of the tumor, is screened, and ARRDC2 is suggested, as a marker molecule, to be applied to determination of the development of the oral squamous cell carcinoma, prediction of the prognosis of the tumor and guiding of therapeutic plans and curative effect monitoring.

The invention discloses a target gene for diagnosis of oral squamous cell carcinoma and application thereof. By screening genes with an expression level related to a tumor differentiation level, the expression of genes in tumor tissues in each differentiation level is determined, so that the differentiation level of a tumor is determined, thereby accurately and objectively predicting the tumor prognosis, guiding the formulation of a treatment plan and monitoring a therapeutic effect.

The invention provides nanoparticles for Raman spectrum detection of oral squamous cell carcinoma tumor cells. The nanoparticles for Raman spectrum detection of the oral squamous cell carcinoma tumorcells are prepared from nanoscale gold particles and 4-mercaptobenzoic acid, alpha-sulfydryl-omega-carboxyl polyethylene glycol and an EGFR antibody through response. The nanoparticles for Raman spectrum detection of oral squamous cell carcinoma tumor cells can be combined with the characteristics of the oral squamous cell carcinoma tumor cells, so that specific Raman signals are obtained, and theoral squamous cell carcinoma tumor cells are rapidly and accurately detected in real time in situ; compared with traditional frozen pathological tissue section examination, the time is saved, accuracy is improved, and a novel detection method for detecting whether oral squamous cell carcinoma cells remain or not in clinical operations is provided.

The invention provides a reagent kit for diagnosing oral squamous cell carcinoma. The reagent kit comprises specific antibodies for detecting HOXA10, specific antibodies for detecting HOXA11, specific antibodies for detecting HOXC6 or compositions with more than one or two optional specific antibodies for detecting the expression quantities of HOXC8. The reagent kit has the advantages that sequencing results for mRNA [messenger RNA (ribonucleic acid)] of the oral squamous cell carcinoma and normal oral tissues in TCGA (the cancer genome atlas) databases are statistically analyzed, data of 32 cases of normal oral tissues and 341 cases of oral squamous cell carcinoma tissues are incorporated, obvious difference of expression of partial genes in HOX families in the oral squamous cell carcinoma and the normal tissues is discovered, and accordingly the reagent kit is suitable to be applied to diagnosing the oral squamous cell carcinoma; expression of genes in the HOX families is detected in oral squamous cell carcinoma tissue pathological sections by the aid of immunohistochemical processes, and accordingly positive expression of the genes in the oral squamous cell carcinoma and application values of the genes in diagnosis can be determined.

The invention relates to the technical field of biological medicines, and provides application of vitamin C in preparation of products for inhibiting human oral squamous cell carcinoma (OSCC). The products for inhibiting the human OSCC comprise drugs for treating the human OSCC, and health care food or health care drink for preventing the human OSCC. It is verified by cell experiments and animal experiments that the vitamin C can inhibit the growth of human OSCC cells, increases the apoptosis of the human OSCC cells, inhibits the growth of nude mouse transplanted tumors at the same time, and is better in inhibitory effect on tumors in combination with cis-platinum, so that it is shown that the vitamin C has the effect of inhibiting the human OSCC. Therefore, the vitamin C is to become a novel drug for inhibiting the human OSCC, and new exploration is provided for the prevention or treatment of the human OSCC.

The invention provides an application of verbascoside in preparation of a medicine for treating oral squamous cell carcinoma. By intraperitoneal injection of verbascoside into a tumor-bearing mouse with oral squamous cell carcinoma, it is observed that the verbascoside can effectively inhibit the growth of oral squamous cell carcinoma tumors by promoting tumor cell apoptosis. Moreover, the verbascoside provided by the invention, at cell and animal levels, achieves an effect of effectively resisting squamous cell carcinoma by inhibiting proliferation of HN4 cells of the oral squamous cell carcinoma and inducing apoptosis of the HN4 cells.

The invention discloses application of miR-302b-3p as an anti-tumor marker of oral squamous cell carcinoma, and belongs to the field of tumor diagnosis and treatment. The application is divided into two aspects: firstly, the miR-302b-3p detection reagent is used for preparing a diagnostic kit for the invasiveness and/or migration of the oral squamous cell carcinoma, and secondly, the miR-302b-3p or a miR-302b-3p precursor is used as an active ingredient for preparing a medicine for delaying the invasion and/or migration of the oral squamous cell carcinoma. The application provides a new direction for diagnosis and treatment of oral squamous cell carcinoma, and has a very good application prospect.

The invention discloses a mouse-derived oral squamous cell carcinoma cell strain,and a preparation method and application thereof, and the preparation method comprises the following steps: firstly, adding 4-nitroquinoline-N-oxide into mouse drinking water, inducing mouse oral squamous cell carcinoma, and obtaining mouse oral squamous cell carcinoma tumor tissues; carrying out digestion and primary culture on the mouse tumor tissue to obtain mouse tumor primary cells; selecting a monoclonal cell from the primary cells by adopting a monoclonal screening method; and purifying the monoclonal cells, carrying out continuous passage, and screening out a cell strain to obtain the mouse oral squamous cell carcinoma cell strain. The mouse squamous cell carcinoma cells can form tumors on both immunodeficient nude mice and immune-healthy C57BL/6J mice, so that the problem that the existing human oral squamous cell carcinoma cell line has poor tumor forming effect on immune-healthy mice is solved; the invention has an important value in establishment of a tumor immune mouse model and research of a subsequent interaction mechanism of a tumor and an immune system.

A bifunctional nucleoside hydrogel is formed by dissolving isoguanosine, guanosine and a borate in water or an aqueous solution and then crosslinking same. The bifunctional nucleoside hydrogel integrates a carrier and a drug effect and has a significant inhibitory effect on the activity of tumor cells, and in particular has a significant inhibitory effect on the activity of cells related to lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma and tongue squamous cell carcinoma, of which the inhibitory effect on the activity of cells related to oral squamous cell carcinoma is the best. Therefore, the bifunctional nucleoside hydrogel has potential application prospects in preparing anti-tumor drugs, and particularly, same can provide a new approach for treating oral squamous cell carcinoma.

The invention discloses an oral squamous cell carcinoma differentiation degree prediction system, and belongs to the field of disease diagnosis and artificial intelligence. The system comprises an input module, a prediction module and an output module. The input module is used for inputting pathological section image data; the prediction module is internally provided with an OfficientNets model; and the output module is used for outputting the slice map which is subjected to region marking according to the differentiation degree. The prediction system is high in prediction accuracy of the differentiation degree of the oral squamous cell carcinoma, and is superior to an existing method for predicting other cancers through deep learning.